Modular antigen transportation molecules and uses therof

US10919945B2 · kind B2 · utility

Inventors

• Horst Rose · Burgdorf, DE
• Dania Birte REICHE · Bingen, DE
• Harald Tammen · Hannover, DE

Key dates

• Filing date: Jan 29, 2018
• Grant date: Feb 16, 2021
• Expiry date: Jun 18, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/40
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to (isolated) recombinant proteins, also referred to as improved MAT (iMAT) molecules, comprising at least one translocation module, at least one targeting module and at least one antigen module, wherein at least one cysteine residue is substituted with a different amino acid residue. Such iMAT molecules are useful specifically as vaccines, e.g., for therapy and/or prevention of allergies and/or infectious diseases and/or prevention of transmission of infectious diseases in equines. The present invention further relates to nucleic acids encoding such iMAT molecules, corresponding vectors and primary cells or cell lines.